Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi

Authors: Dennis Miyoge Ongubo, Robertino Lim, Hannock Tweya, Christopher Chikhosi Stanley, Petros Tembo, Richard Broadhurst, Salem Gugsa, McNeil Ngongondo, Colin Speight, Tom Heller, Sam Phiri, Mina C. Hosseinipour

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Malawi’s national antiretroviral therapy program provides atazanavir/ritonavir–based second line regimens which cause concentration-dependent rise in indirect bilirubin. We sought to determine if elevated bilirubin, as a surrogate of atazanavir/ritonavir adherence, can aid in the evaluation of second line virological failure in Malawi.

Methods

We conducted a cross-sectional study of HIV-infected patients ≥15 years who were on boosted protease inhibitor-based second line antiretroviral therapy for at least 6 months in two urban HIV clinics in Lilongwe, Malawi. Antiretroviral therapy history and adherence data were extracted from the electronic medical records and blood was drawn for viral load, complete blood count, total bilirubin, and CD4 cell count at a clinic visit. Factors associated with virological failure were assessed using multivariate logistic regression model.

Results

Out of 376 patients on second line antiretroviral therapy evaluated, 372 (98.9%) were on atazanavir/ritonavir-based therapy and 142 (37.8%) were male. Mean age was 40.9 years (SD ± 10.1), mean duration on second line antiretroviral therapy was 41.9 months (SD ± 27.6) and 256 patients (68.1%) had elevated bilirubin >1.3 mg/dL. Overall, 35 (9.3%) patients had viral load >1000 copies/ml (virological failure). Among the virologically failing vs. non-failing patients, bilirubin was elevated in 34.3% vs. 72.0% respectively (p < 0.001), although adherence by pill count was similar (62.9% vs. 60.7%, p = 0.804). The odds of virological failure were higher for adults aged 25–40 years (adjusted odds ratio (aOR) 2.5, p = 0.048), those with CD4 cell count <100 (aOR 17.5, p < 0.001), and those with normal bilirubin levels (aOR 5.4, p < 0.001); but were lower for the overweight/obese patients (aOR 0.3, p = 0.026). Poor pill count adherence (aOR 0.7, p = 0.4) and male gender (aOR 1.2, p = 0.698) were not associated with second line virological failure.

Conclusions

Among patients receiving atazanavir/ritonavir-based second line antiretroviral therapy, bilirubin levels better predicted virological failure than pill count adherence. Therefore, strategic use of bilirubin and viral load testing to target adherence counseling and support may be cost-effective in monitoring second line antiretroviral therapy adherence and virological failure. Drug resistance testing targeted for patients with virological failure despite elevated bilirubin levels would facilitate timely switch to third line antiretroviral regimens whenever available.
Literature
1.
Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A, et al. ART-LINC of IeDEA Study Group: Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(2):251–8.CrossRefPubMed
2.
Hosseinipour MC, Kumwenda JJ, Weigel R, Brown LB, Mzinganjira D, Mhango B, Eron JJ, Phiri S, van Oosterhout JJ: Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline HIV Med 2010, 11(8):510–518.
3.
Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, Arendt V, et al. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. The Lancet Infectious Diseases. 2010;10(1):60–5.CrossRefPubMed
4.
Boyd M, Emery S, Cooper DA. Antiretroviral roll-out: the problem of second-line therapy. The Lancet. 2009;374(9685):185–6.CrossRef
5.
Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. IeDEA Southern Africa Collaboration: Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25(14):1761–9.CrossRefPubMedPubMedCentral
6.
Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, Mwako MS, Masaki LJ, Mmbando CE, Minja MG, Lirhunde ES, Miller WC: Association of first-line and second-line antiretroviral therapy adherence Open Forum Infect Dis 2014, 1(2):ofu079.
7.
Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, et al. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One. 2012;7(5):e36997.CrossRefPubMedPubMedCentral
8.
Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3(1):27–34.CrossRefPubMedPubMedCentral
9.
Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):e32144.CrossRefPubMedPubMedCentral
10.
Ajose O, Mookerjee S, Mills E, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929–38.CrossRefPubMed
11.
Khan S, Das M, Andries A, Deshpande A, Mansoor H, Saranchuk P, et al. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai. India Glob Health Action. 2014;7:24861.CrossRefPubMed
12.
Chakravarty J, Sundar S, Chourasia A, Singh PN, Kurle S, Tripathy SP, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15:517–015–1270-8.CrossRef
13.
Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis. 2013;207(Suppl 2):S49–56.CrossRefPubMedPubMedCentral
14.
Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12(1):83–8.PubMed
15.
Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009;103(6):601–6.CrossRefPubMed
16.
Ministry of Health. Malawi Guidelines for Clinical Management of HIV in Children and Adults: second edition ed. Lilongwe, Malawi: Ministry of Health; 2014.
17.
Zhang D, Chando T, Everett D, Patten C, Dehal S, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33(11):1729–39.CrossRefPubMed
18.
Smith D, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006;7(1):34–8.CrossRefPubMed
19.
Cleijsen RMM, Van de Ende, M E, Kroon FP, Lunel FV, Koopmans PP, Gras L, de wolf F, burger DM: therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007, 60(4):897–900.
20.
Barrios A, Rendón A, Gallego O, Martín Carbonero L, Valer L, Ríos P, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004;5(4):201–5.CrossRefPubMed
21.
Laprise C, Baril JG, Dufresne S, Trottier H. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up. AIDS Patient Care STDs. 2013;27(7):378–86.CrossRefPubMedPubMedCentral
22.
Petersen K, Riddle M, Jones L, Furtek K, Christensen A, Tasker S, et al. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS. 2005;19(15):1700–2.CrossRefPubMed
23.
Douglas G, Gadabu O, Joukes S, Mumba S, McKay M, Ben Smith A, et al. Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med. 2010:7(8).
24.
Paterson DL. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Ann Intern Med. 2000;133(1):21.CrossRefPubMed
25.
Pujades Rodríguez M, Balkan S, Arnould L, Brinkhof MAW, Calmy A. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304(3):303–12.CrossRefPubMed
26.
Rupérez M, Pou C, Maculuve S, Cedeño S, Luis L, Rodríguez J, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639–47.CrossRefPubMed
27.
Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. IeDEA-SA collaboration: Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):428–37.CrossRefPubMedPubMedCentral
28.
Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al. Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors. Clinical Infectious Diseases. 2005;40(1):158–63.CrossRefPubMed
29.
van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333–9.CrossRefPubMedPubMedCentral
30.
Akanmu AS, Adeyemo T, Lesi F, Bello FO, Okwuegbuna K, Oloko K, et al. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens. Curr HIV Res. 2015;13(3):176–83.CrossRefPubMed
31.
Duong M, Piroth L, Peytavin G, Forte F, Kohli E, Grappin M, et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis. 2001;33(3):386–92.CrossRefPubMed
32.
Gandhi M, Ameli N, Bacchetti P, Anastos K, Gange SJ, Minkoff H, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52(10):1267–75.CrossRefPubMedPubMedCentral
33.
Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One. 2012;7(5):e36737.CrossRefPubMedPubMedCentral
34.
Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, Kityo C, Thomason M, Kabamba D, Chintu C, Gibb DM, Bangsberg DR: Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects PLoS One 2011, 6(4):e18505.
35.
Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968–77.CrossRefPubMed
36.
Morello J, Alvarez E, Cuenca L, Vispo E, González Lahoz J, Soriano V, et al. Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. AIDS Res Hum Retrovir. 2011;27(10):1043–5.CrossRefPubMed
37.
Rekic D, Clewe O, Röshammar D, Flamholc L, Sönnerborg A, Ormaasen V, et al. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J. 2011;13(4):598–605.CrossRefPubMedPubMedCentral
38.
Win MM, Maek-A-Nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparph S. Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. J Int Assoc Physicians AIDS Care (Chic). 2011;10(1):57–63.CrossRef
39.
Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012;26(9):1083–93.CrossRefPubMedPubMedCentral
40.
Harrigan PR, Rhee S, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AMJ, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW: HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing PLOS ONE 2015, 10(12):e0145772.
41.
Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009;23(9):1127–34.CrossRefPubMedPubMedCentral
42.
Oosterhout v, Joep JG, Brown L, Weigel R, Kumwenda J, Mzinganjira D, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Tropical Med Int Health. 2009;14(8):856–61.CrossRef
43.
Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. ART-LINC Collaboration of the International Databases to Evaluate AIDS (IeDEA): Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health. 2009;14(10):1220–5.CrossRefPubMedPubMedCentral
44.
Moore DM, Awor A, Downing R, Kaplan J, Montaner JSG, Hancock J, et al. CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy. JAIDS J Acquired Immune Defic Syndromes. 2008;49(5):477–84.CrossRef
45.
Mee P, Fielding K, Charalambous S, Churchyard G, Grant A. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22(15):1971–7.CrossRefPubMed
46.
Khienprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Research and Therapy. 2011;8(1):42.CrossRefPubMedPubMedCentral
47.
Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2006;41(3):385–92.CrossRefPubMed
48.
Vanobberghen FM, Kilama B, Wringe A, Ramadhani A, Zaba B, Mmbando D, Todd J: Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data Tropical Medicine & International Health 2015; 2015, 20(7):880–892.
49.
Anglaret X. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. Bull World Health Organ. 2008;2008(6):435–42.CrossRef
50.
Boulle C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kaze S, Dontsop M, Mben JM, Koulla-Shiro S, Peytavin G, Spire B, Delaporte E, Laurent C, Stratall ANRS 12110ESTHER Study Group: Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon J Acquir Immune Defic Syndr 2015, 69(3):355–364.
51.
Jones LR, Moretti F, Calvo AY, Dilernia DA, Manrique JM, Gomez-Carrillo M, et al. Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues. AIDS Res Hum Retroviruses. 2012;28(8):949–55.CrossRefPubMedPubMedCentral
52.
Penot P, Hema A, Bado G, Kabore F, Sore I, Sombie D, et al. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso. J Int AIDS Soc. 2014;17:18646.CrossRefPubMedPubMedCentral
53.
Levison J, Orrell C, Gallien S, Kuritzkes D, Fu N, Losina E, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):e32144.CrossRefPubMedPubMedCentral
54.
Okatch H, Beiter K, Eby J, Chapman J, Marukutira T, Tshume O, et al. Brief Report: Apparent Antiretroviral Overadherence by Pill Count is Associated With HIV Treatment Failure in Adolescents. J Acquir Immune Defic Syndr. 2016;72(5):542–5.PubMed
55.
Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial Lancet 1999, 353(9171):2195–2199.
Metadata
Title
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi
Authors
Dennis Miyoge Ongubo
Robertino Lim
Hannock Tweya
Christopher Chikhosi Stanley
Petros Tembo
Richard Broadhurst
Salem Gugsa
McNeil Ngongondo
Colin Speight
Tom Heller
Sam Phiri
Mina C. Hosseinipour
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2528-0

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue

Research article

A case control study on family history as a risk factor for herpes zoster and associated outcomes, Beijing, China

Research article

Comparing antibiotic treatment for leptospirosis using network meta-analysis: a tutorial

Case report

Spondylodiscitis due to Parvimonas micra diagnosed by the melting temperature mapping method: a case report

Research article

Molecular epidemiology of bla OXA-23 -producing carbapenem-resistant Acinetobacter baumannii in a single institution over a 65-month period in north China

Research article

Total delay in treatment among tuberculous meningitis patients in China: a retrospective cohort study

Research article

An evaluation of a recombinant multiepitope based antigen for detection of Toxoplasma gondii specific antibodies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits